Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...
Inovio Pharmaceuticals Inc. closed 54.49% below its 52-week high of $4.44, which the company reached on December 9th.
The stock's fall snapped a two-day winning streak.
Zacks.com on MSN
Inovio (INO) Upgraded to Buy: Here's Why
Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
In addition to Piper Sandler, Inovio Pharmaceuticals also received a Buy from Oppenheimer’s Hartaj Singh in a report issued on November 11. However, on the same day, TR | OpenAI – 4o reiterated a Hold ...
Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa ...
The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the next wave of breakthroughs may come from companies flying well below Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results